Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Melatonin effects on glucose and lipid profile in type 2 diabetes mellitus
IRCT2012062610115N1Phase 3Completed
- Sponsor
- Arak University of Medical Sciences
- Start
- Jan 2012
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3 trial of melatonin in type 2 diabetes mellitus (T2DM), sponsored by Arak University of Medical Sciences. Primary endpoints: Change in glucose profile and Change in lipid profile. Started Jan 2012; status: completed.
02
Drugs
melatonin
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on IRCT2012062610115N1.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT2012062610115N1.